Lewis rats are not susceptible to oral infection with Mycobacterium avium subsp. paratuberculosis.
Pathogenesis studies of Mycobacterium avium subsp. paratuberculosis infection in ruminants are hampered by the long incubation time of the disease. A laboratory animal model with a shorter incubation time would facilitate research in this field. Although small rodents are usually considered to be resistant to M.a. paratuberculosis infection, several susceptible murine strains have been found. To our knowledge, there are no detailed reports with regard to susceptibility in rats. The Lewis rat is a valuable model for inflammatory bowel disease studies as well as autoimmune diseases involving mycobacteria as inducing agents. In this study Lewis rats were used to investigate their potential as a small laboratory animal model for paratuberculosis. In total 28 female Lewis rats were orally inoculated with M.a. paratuberculosis. The rats were first inoculated at 3 weeks of age, and 12 more inoculations followed in increasing intervals during the 3 months to follow. Eight control rats received a sham inoculation. Over 9 months, two rats from each group were sacrificed at regular intervals and immunological and histopathological examinations were performed on the gastrointestinal tract, the liver and the spleen. None of the rats developed lesions which were indicative of mycobacterial infection as determined by histology with HE and Ziehl-Neelsen staining. The bacteria could not be recultured from samples taken from the gut, the liver or the spleen. The immunological tests however, showed that bacteria had entered via the intestinal tract. From this study it appears that Lewis rats are resistant to oral inoculation with M. a. paratuberculosis, and not suitable as a model to study the immunopathogenesis of paratuberculosis as it occurs in ruminants.
Koets
A P
AP
Department of Immunology, Faculty of Veterinary Medicine, Institute of Infectious Diseases and Immunology, Utrecht University, PO Box 80. 165, 3508 TD, Utrecht, Netherlands.
Rutten
V P
VP
Bakker
D
D
van der Hage
M H
MH
van Eden
W
W
D000284:Administration, Oral; D000818:Animals; D001426:Bacterial Proteins; D018834:Chaperonin 60; D018833:Chaperonins / Q000032:analysis; D004195:Disease Models, Animal; D004198:Disease Susceptibility / Q000662:veterinary; D004797:Enzyme-Linked Immunosorbent Assay / Q000662:veterinary; D005260:Female; D018840:HSP70 Heat-Shock Proteins / Q000008:administration & dosage / Q000276:immunology; D007279:Injections, Subcutaneous / Q000662:veterinary; D008213:Lymphocyte Activation; D016927:Mycobacterium avium subsp. paratuberculosis / Q000276:immunology; D010283:Paratuberculosis / Q000276:immunology*; D011897:Random Allocation; D051381:Rats; D011917:Rats, Inbred Lew / Q000276:immunology*; D012376:Rodent Diseases / Q000276:immunology*
D001426:Bacterial Proteins; D018834:Chaperonin 60; D018840:HSP70 Heat-Shock Proteins; C074119:heat-shock protein 65, Mycobacterium; D018833:Chaperonins